Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights
– Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO –
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye, today announced third quarter 2020 financial results and recent business highlights.
“We continue to make strong progress across our classical complement platform, including expanded development of ANX005 in Huntington’s Disease, and advancement of our subcutaneous formulation, ANX009, into the clinic,” said Douglas Love, Esq., president and chief executive officer of Annexon. “Our unique focus on C1q allows us to address a diverse set of classical complement-mediated autoimmune and neurodegenerative diseases, and we’re well capitalized to conduct several promising near- and mid-term Phase 2 clinical trials in these devastating diseases.”
Anticipated Upcoming Milestones
Third Quarter 2020 Financial Results
About Annexon, Inc.
Forward Looking Statements
Investor Contact: Sylvia Wheeler email@example.com Alexandra Santos firstname.lastname@example.org Media Contact: Caroline Rufo, Ph.D. email@example.com
Connectivity Management: Change is Gonna Come